Replies to post #497850 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

Very good observations...

[investingdog]

Key Observations

Scope and Sensitivity: ADAS-Cog13 is an extension of ADAS-Cog11, adding delayed word recall and number cancellation to better capture early AD changes and executive function. This makes ADAS-Cog13 more suitable for trials in early or prodromal AD (e.g., blarcamesine), while ADAS-Cog11 remains effective for mild-to-moderate AD (e.g., zervimesine, buntanetap).
Scoring and Interpretation: ADAS-Cog13’s higher scoring range (0–85) provides greater resolution for tracking subtle cognitive changes, but its complexity can complicate administration. ADAS-Cog11 (0–70) is simpler but may miss nuanced effects in early stages.
Trial Context: In the trials discussed, ADAS-Cog13 (blarcamesine) detected significant slowing of decline in early AD, while ADAS-Cog11 (zervimesine, buntanetap) showed benefits in mild-to-moderate AD, with buntanetap uniquely reporting cognitive improvement rather than just slowing decline.

[WilliamMunny]

You might want to ask GROK for a couple of other observations: Liquidity - how much cash do CGTX and ANVS have to carry out their Phase 3 trials, compared to AVXL, which has finished its Phase 3 trial; and also Filing Status - which has an application for drug approval at the FDA or EMA, and, for those who have not, how long will it be before they could likely make a filing.

[georgejjl]

You said

“… Dropouts and Safety: Buntanetap had the lowest dropout rate; blarcamesine the highest (typical for longer AD trials)...,

Keep in mind this trial occurred during the worldwide COVID pandemic. Therefore that was the reason for the high dropout rate.

GOD bless,